Drug intelligence / Profile preview

hpDNA-EP

Development stage: Unknown
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Delivered By Electroporation

Overview

hpDNA-EP is a synthetic linear hairpin DNA vaccine platform delivered via electroporation (EP). It is designed to rapidly and cost-effectively induce strong CD8+ and CD4+ T cell responses against tumor-specific neoantigens. This platform has shown promise in preclinical studies for personalized cancer vaccines, demonstrating significant tumor protection and reduction of metastases, and has been evaluated in a Phase I COVID-19 trial. Its synthetic biology-based approach aims to provide a feasible and promising alternative immunotherapy for cancer, particularly in neoadjuvant settings.

Targets

pMHC (Peptide-MHC complex family)

Beyond the preview

Go deeper on hpDNA-EP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on hpDNA-EP.

Explore the full profile